title: Targeting of prosurvival pathways as therapeutic approaches against primary effusion lymphomas: past, present, and Future.
abstract: Constitutively activated prosurvival pathways render cancer cells addicted to their effects. Consequently they turn out to be the Achilles' heels whose inhibition can be exploited in anticancer therapy. Primary effusion lymphomas (PELs) are very aggressive non-Hodgkin's B cell lymphomas, whose pathogenesis is strictly linked to Kaposi's sarcoma herpesvirus (KSHV) infection. Here we summarized previous studies from our and other laboratories exploring the cytotoxic effect of drugs inhibiting the main prosurvival pathways activated in PEL cells. Moreover, the immunogenicity of cell death, in terms of dendritic cell (DC) activation and their potential side effect on DCs, is discussed.
authors.affiliation: Department of Experimental Medicine, Istituto Pasteur Fondazione Cenci Bolognetti, Sapienza University, 00161 Rome, Italy.
authors.forename: Marisa
authors.initials: M
authors.lastname: Granato
authors.affiliation: Department of Experimental Medicine, Istituto Pasteur Fondazione Cenci Bolognetti, Sapienza University, 00161 Rome, Italy.
authors.forename: Roberta
authors.initials: R
authors.lastname: Santarelli
authors.affiliation: Department of Experimental Medicine, Istituto Pasteur Fondazione Cenci Bolognetti, Sapienza University, 00161 Rome, Italy.
authors.forename: Roberta
authors.identifier: 0000-0003-4894-4986
authors.initials: R
authors.lastname: Gonnella
authors.affiliation: Department of Experimental Medicine, Istituto Pasteur Fondazione Cenci Bolognetti, Sapienza University, 00161 Rome, Italy.
authors.forename: Antonella
authors.identifier: 0000-0002-8629-0971
authors.initials: A
authors.lastname: Farina
authors.affiliation: Department of Experimental Medicine, Istituto Pasteur Fondazione Cenci Bolognetti, Sapienza University, 00161 Rome, Italy.
authors.forename: Pankaj
authors.identifier: 0000-0001-9574-6304
authors.initials: P
authors.lastname: Trivedi
authors.affiliation: Department of Experimental Medicine, Istituto Pasteur Fondazione Cenci Bolognetti, Sapienza University, 00161 Rome, Italy.
authors.forename: Alberto
authors.initials: A
authors.lastname: Faggioni
authors.affiliation: Department of Experimental Medicine, Istituto Pasteur Fondazione Cenci Bolognetti, Sapienza University, 00161 Rome, Italy.
authors.forename: Mara
authors.initials: M
authors.lastname: Cirone
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D016923:Cell Death / Q000187:drug effects; D003713:Dendritic Cells / Q000187:drug effects / Q000821:virology; D019288:Herpesvirus 8, Human / Q000187:drug effects; D006801:Humans; D054685:Lymphoma, Primary Effusion / Q000188:drug therapy* / Q000821:virology
chemical_list: D000998:Antiviral Agents